CCCC Q2 2021 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+1.1% YoY

Gross Profit

-$14M-138.1% margin

Operating Income

-$22M-226.1% margin

Net Income

-$23M-230.9% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+31.7%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$19M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$528M

Total Liabilities

$112M

Stockholders' Equity

$416M

Cash & Equivalents

$281M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$10M	+1.1%
Gross Profit	-$14M	$10M	-239.7%
Operating Income	-$22M	-$11M	-103.7%
Net Income	-$23M	-$11M	-109.2%